Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.81 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105377 | 0.95 | CHRNB2 (0.84) | CHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL29784945 | 0.90 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL12827198 | 0.90 | CHRNB2 (1.00) | CHRNB2CHRNA4 | |
| SCHEMBL22831347 | 0.83 | CHRNB2 (0.87) | CHRNB2CHRNA4 | |
| SCHEMBL20730105 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9367178 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30542607 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19055583 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4888697 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3229561 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003500393-A | — | — | 2003-01-07 | — | — | JP | claimed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | claimed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | claimed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | claimed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | claimed |
| CN-108026105-A | Tgf beta receptor antagonists | 百时美施贵宝公司 | 2018-05-11 | — | — | CN | disclosed |
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | CHRNB2 98/4885CHRNA4 32/4885KDM4E 1009/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | CHRNB2 32/4885CHRNA4 34/4885KDM4E 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.